The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis
Schizophrenia Bulletin · 08.05.2025 · 51 (3) · 625-636
DOI: 10.1093/schbul/sbae173 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Schizophrenia Bulletin, online erschienen am 07.11.2024. Verfasst von Tzu-Rong Peng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231016, Taiwan. Hauptthemen laut MEDLINE: Metformin, Weight Gain, Antipsychotic Agents, Schizophrenia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Weight gain and metabolic complications are substantial adverse effects associated with second-generation antipsychotics. However, comprehensive guidelines for managing antipsychotic-induced weight gain are lacking.
Methods
This review included all double-blind, placebo-controlled studies investigating metformin’s effectiveness in addressing antipsychotic-related weight gain. We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Google Scholar, and ClinicalTrials.gov for relevant studies from the inception to 2024. A random-effects model was used for the meta-analysis.
Results
This meta-analysis, including 20 studies with 1070 patients, revealed that metformin significantly surpassed placebo in attenuating weight gain in patients receiving antipsychotics. The mean weight change with metformin was −3.32 kg [95% confidence interval (CI): −4.57 to −2.07]. Additionally, metformin use resulted in a marked decrease in body mass index [−1.24 kg/m2 (95% CI: −1.70 to −0.77)]. Metformin could maintain the effects from 12 to 24 weeks.
Conclusions
This updated meta-analysis investigated the durations and dosages of metformin use in patients with schizophrenia experiencing antipsychotic-induced weight gain. The findings highlight the need for additional large-scale research to validate our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231016, Taiwan.
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.
- Graduate Institute of Counseling Psychology and Rehabilitation Counseling, National Kaohsiung Normal University, Kaohsiung 80201, Taiwan.
- Department of Pharmacy, New Taipei City Hospital, New Taipei City 24141, Taiwan.
- Department of Nursing, Cardinal Tien College of Healthcare and Management, New Taipei City 231038, Taiwan.
ORCID-Profile: Tzu-Rong Peng
Zitieren
APA
Peng, T. R., Chen, J. A., Lee, J. A., Hsing, C. P., Lee, M. C., & Chen, S. M. (2025). The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis. Schizophrenia Bulletin, 51(3), 625-636. https://doi.org/10.1093/schbul/sbae173
Vancouver
Peng TR, Chen JA, Lee JA, Hsing CP, Lee MC, Chen SM. The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis. Schizophrenia Bulletin. 2025;51(3):625-636. doi:10.1093/schbul/sbae173
BibTeX
@article{Peng2025,
author = {Peng, Tzu-Rong and Chen, Jou-An and Lee, Jen-Ai and Hsing, Chih-Pin and Lee, Ming-Chia and Chen, Shih-Ming},
title = {The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis},
journal = {Schizophrenia Bulletin},
year = {2025},
volume = {51},
number = {3},
pages = {625--636},
doi = {10.1093/schbul/sbae173}
}
EUVIMED